$0.88
-0.01 (-1.03%)
Open$0.91
Previous Close$0.89
Day High$0.93
Day Low$0.88
52W High$209.50
52W Low—
Volume—
Avg Volume332.9K
Market Cap3.52M
P/E Ratio—
EPS$-219.70
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+313.6% upside
Current
$0.88
$0.88
Target
$3.65
$3.65
$2.40
$3.65 avg
$4.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 168.33M | 335.8K | 347.3K |
| Net Income | -2,896,991,737 | 43.0K | 52.4K |
| Profit Margin | -1,721.0% | 12.8% | 15.1% |
| EBITDA | -4,835,631,156 | 73.2K | 78.8K |
| Free Cash Flow | — | 45.7K | 64.8K |
| Rev Growth | — | +0.6% | +12.6% |
| Debt/Equity | — | 0.59 | 0.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |